Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310102641> ?p ?o ?g. }
- W4310102641 endingPage "9124" @default.
- W4310102641 startingPage "9122" @default.
- W4310102641 abstract "Introduction: An emerging trend for targeted treatment in AML has led to increased treatment options, however variable outcomes remain even with a targeted approach suggesting novel approaches are needed. To date, risk stratification of AML patients has relied on cytogenetic and genomic data as there has been no CLIA-certified biomarker to assess how leukemia stem cells (LSC) contribute to disease resistance at a clinical level. The LSC17 score predicts risk based on stemness features in AML patients at diagnosis and is strongly associated with survival after standard induction therapy (Ng, Nature 2016). A NanoString clinical assay for the LSC17 score has recently been validated in a CLIA-certified laboratory (Ng, Blood Advances 2022) and can provide a rapid result within 72 hours of diagnosis for incorporation into upfront treatment decisions. Recent updates in AML have led to an improved risk stratification at cytogenetic and genomic levels (ELN 2022). Here we carried out a new analysis to assess the value of the LSC17 score as an independent predictor of outcomes in AML patients in the context of the updated ELN 2022 classification. Methods: Data from recent validation and prospective feasibility studies were analyzed. Only patients that received induction chemotherapy were included in the analysis. Patients with a confirmed diagnosis of acute promyelocytic leukemia were excluded from analysis. In our studies the LSC17 score was measured in parallel with standard prognostic markers including cytogenetics, molecular studies and targeted sequencing using a standard myeloid panel. Patients’ ELN status was updated using the 2022 classification scheme and was correlated with treatment response and survival. Results: 190 patients were included in our analysis. LSC17 scores ranged from 0 to 1.25, and were classified as high or low according to the median score of 0.51 from our reference cohort (Ng, Blood Advances 2022). Of the 190 patients, 84 had a low LSC17 score and 106 had a high LSC17 score. Patients received induction chemotherapy with three different protocols: standard 3+7 (n = 141), Flag-IDA (n =40) and CPX-351 (n = 9). We first considered the impact of the ELN 2022 classification and how it altered prognostic categorization in our cohort. Using ELN 2017 criteria, 48 (27%), 51 (29%), and 77 (44%) of patients had favorable, intermediate and adverse risk disease, respectively. 14 patients were not classifiable as cytogenetic testing failed. Using the ELN 2022 hierarchical classification, patients were categorized into low (n=44), intermediate (n = 53) and high (n = 93) risk groups. Changes in prognostic classification were most evident in the intermediate risk category where 11 patients were upgraded to high-risk disease due to the presence of myelodysplasia-related disease mutations. When the LSC17 score was considered as a continuous variable, the median LSC17 score was statistically different between the three ELN 2022 risk groups (0.24 [range 0-0.8] vs 0.48 [range 0.04-1.13] vs 0.73 [range 0.14-1.25] for low, intermediate and high-risk, respectively; P<0.001, Figure 1). Measurable residual disease (RD) is associated with poor clinical outcomes. Prediction of RD can identify patients who may benefit from alternative treatment approaches. We therefore assessed the ability of the LSC17 score to predict RD positivity after induction chemo in the context of ELN 2022. In our cohort, 141 patients (74%) had RD testing performed after induction. In univariate analysis, RD positivity was associated with both ELN 2022 high-risk disease (P=0.001, OR 12.7) and a high LSC17 score (P<0.001, OR = 7.7). In multivariate analysis incorporating both variables, both ELN high risk (P=0.02, OR 5.56, 95% CI 1.35 -22.85) and high LSC17 score (P=0.007, OR 3.98, 95% CI 1.44 -11.01) retained independent prognostic value. Conclusion: The LSC17 score measured by the clinical NanoString-based assay correlates with the updated ELN 2022 risk classification and importantly is an independent predictor of RD positivity irrespective of mutational status. Measurement of the LSC17 score at diagnosis will enable identification of patients with high probability of treatment refractoriness. This study highlights the potential role of the LSC17 score in future risk-adapted clinical studies of novel induction candidates. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
- W4310102641 created "2022-11-30" @default.
- W4310102641 creator A5002489867 @default.
- W4310102641 creator A5005430646 @default.
- W4310102641 creator A5005732843 @default.
- W4310102641 creator A5011840011 @default.
- W4310102641 creator A5023965566 @default.
- W4310102641 creator A5026397928 @default.
- W4310102641 creator A5028838867 @default.
- W4310102641 creator A5035022718 @default.
- W4310102641 creator A5037110889 @default.
- W4310102641 creator A5037709424 @default.
- W4310102641 creator A5038592699 @default.
- W4310102641 creator A5044016966 @default.
- W4310102641 creator A5045250493 @default.
- W4310102641 creator A5048157762 @default.
- W4310102641 creator A5048739197 @default.
- W4310102641 creator A5049924678 @default.
- W4310102641 creator A5055906478 @default.
- W4310102641 creator A5058235020 @default.
- W4310102641 creator A5059745705 @default.
- W4310102641 creator A5064197882 @default.
- W4310102641 creator A5066224233 @default.
- W4310102641 creator A5081133747 @default.
- W4310102641 creator A5083780768 @default.
- W4310102641 creator A5085305707 @default.
- W4310102641 creator A5089438037 @default.
- W4310102641 creator A5091426844 @default.
- W4310102641 date "2022-11-15" @default.
- W4310102641 modified "2023-09-27" @default.
- W4310102641 title "The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy" @default.
- W4310102641 doi "https://doi.org/10.1182/blood-2022-171107" @default.
- W4310102641 hasPublicationYear "2022" @default.
- W4310102641 type Work @default.
- W4310102641 citedByCount "0" @default.
- W4310102641 crossrefType "journal-article" @default.
- W4310102641 hasAuthorship W4310102641A5002489867 @default.
- W4310102641 hasAuthorship W4310102641A5005430646 @default.
- W4310102641 hasAuthorship W4310102641A5005732843 @default.
- W4310102641 hasAuthorship W4310102641A5011840011 @default.
- W4310102641 hasAuthorship W4310102641A5023965566 @default.
- W4310102641 hasAuthorship W4310102641A5026397928 @default.
- W4310102641 hasAuthorship W4310102641A5028838867 @default.
- W4310102641 hasAuthorship W4310102641A5035022718 @default.
- W4310102641 hasAuthorship W4310102641A5037110889 @default.
- W4310102641 hasAuthorship W4310102641A5037709424 @default.
- W4310102641 hasAuthorship W4310102641A5038592699 @default.
- W4310102641 hasAuthorship W4310102641A5044016966 @default.
- W4310102641 hasAuthorship W4310102641A5045250493 @default.
- W4310102641 hasAuthorship W4310102641A5048157762 @default.
- W4310102641 hasAuthorship W4310102641A5048739197 @default.
- W4310102641 hasAuthorship W4310102641A5049924678 @default.
- W4310102641 hasAuthorship W4310102641A5055906478 @default.
- W4310102641 hasAuthorship W4310102641A5058235020 @default.
- W4310102641 hasAuthorship W4310102641A5059745705 @default.
- W4310102641 hasAuthorship W4310102641A5064197882 @default.
- W4310102641 hasAuthorship W4310102641A5066224233 @default.
- W4310102641 hasAuthorship W4310102641A5081133747 @default.
- W4310102641 hasAuthorship W4310102641A5083780768 @default.
- W4310102641 hasAuthorship W4310102641A5085305707 @default.
- W4310102641 hasAuthorship W4310102641A5089438037 @default.
- W4310102641 hasAuthorship W4310102641A5091426844 @default.
- W4310102641 hasBestOaLocation W43101026411 @default.
- W4310102641 hasConcept C126322002 @default.
- W4310102641 hasConcept C143998085 @default.
- W4310102641 hasConcept C2776611710 @default.
- W4310102641 hasConcept C2776694085 @default.
- W4310102641 hasConcept C2778336483 @default.
- W4310102641 hasConcept C2778461978 @default.
- W4310102641 hasConcept C2779134260 @default.
- W4310102641 hasConcept C2779823535 @default.
- W4310102641 hasConcept C71924100 @default.
- W4310102641 hasConceptScore W4310102641C126322002 @default.
- W4310102641 hasConceptScore W4310102641C143998085 @default.
- W4310102641 hasConceptScore W4310102641C2776611710 @default.
- W4310102641 hasConceptScore W4310102641C2776694085 @default.
- W4310102641 hasConceptScore W4310102641C2778336483 @default.
- W4310102641 hasConceptScore W4310102641C2778461978 @default.
- W4310102641 hasConceptScore W4310102641C2779134260 @default.
- W4310102641 hasConceptScore W4310102641C2779823535 @default.
- W4310102641 hasConceptScore W4310102641C71924100 @default.
- W4310102641 hasIssue "Supplement 1" @default.
- W4310102641 hasLocation W43101026411 @default.
- W4310102641 hasOpenAccess W4310102641 @default.
- W4310102641 hasPrimaryLocation W43101026411 @default.
- W4310102641 hasRelatedWork W1561150073 @default.
- W4310102641 hasRelatedWork W1998618181 @default.
- W4310102641 hasRelatedWork W1999020667 @default.
- W4310102641 hasRelatedWork W2034028172 @default.
- W4310102641 hasRelatedWork W2134306396 @default.
- W4310102641 hasRelatedWork W2765458859 @default.
- W4310102641 hasRelatedWork W2954897945 @default.
- W4310102641 hasRelatedWork W2988792442 @default.
- W4310102641 hasRelatedWork W3030916261 @default.
- W4310102641 hasRelatedWork W4244624038 @default.
- W4310102641 hasVolume "140" @default.
- W4310102641 isParatext "false" @default.
- W4310102641 isRetracted "false" @default.